CoChat
Sign Up
Cited by 55Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesHedgehog Signaling Pathway Studies

Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study

Open access
Maytin, Edward V., Kaw, Urvashi, Ilyas, Muneeb, Mack, Judith A., Hu, Bo·2018·Photodiagnosis and Photodynamic Therapy
DOI 10.1016/j.pdpdt.2018.02.009PMC PMC5985214
Open this paper in CoChat — free account

Abstract

Background Photodynamic therapy (PDT) is a non-scarring alternative for treating basal cell carcinoma (BCC) in patients with Basal Cell Nevus Syndrome (BCNS), also known as Gorlin syndrome. In Europe, red light (635 nm) is the predominant source for PDT, whereas in the United States blue light (400 nm) is more widely available. The objective of this study was to conduct a head-to-head comparison of blue light and red light PDT in the same BCNS patients. Methods In a pilot study of three patients with 141 BCC lesions, 5-aminolevulinate (20% solution) was applied to all tumors. After 4 h, half of the tumors were illuminated with blue light and the remainder with red light. To ensure safety while treating this many tumors simultaneously, light doses were escalated gradually. Six treatments were administered in three biweekly sessions over 4 months, with a final evaluation at 6 months. Tumor status was documented with high-resolution photographs. Persistent lesions were biopsied at 6 months. Results Clearance rates after blue light (98%) were slightly better than after red light (93%), with blue light shown to be statistically non-inferior to red light. Eight suspicious lesions were biopsied, 5 after red light (5/5 were BCC) and 3 after blue light (1 was BCC). Blue light PDT was reportedly less painful. Conclusion Blue light and red light PDT appear to be equally safe and perhaps equally effective for treating BCC tumors in BCNS patients. Further studies to evaluate long-term clearance after blue light PDT are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pdpdt.2018.02.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALA-PDT with blue light shows equal efficacy to PDT with red light in clearing BCC lesions at 6 months after treatment.

    “ALA-PDT with blue light shows equal efficacy to PDT with red light in clearing BCC lesions at 6 months after treatment [63].”

    From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [63]

    The Results report similar BCC clearance rates with blue and red light (98% versus 93%), with blue light statistically non-inferior. But the Methods place the final evaluation at six months from the start of the study, while the Discussion describes the clearance results as having two months of follow-up after treatment—not six months after treatment. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. [1]Bree AF Shah MR Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS) Am J Med Genet A 2011 155A 2091 7 21834049
  2. [2]Tom WL Hurley MY Oliver DS Shah MR Bree AF Features of basal cell carcinomas in basal cell nevus syndrome Am J Med Genet A 2011 155A 2098 104 21834051
  3. [3]Kimonis VE Singh KE Zhong R Pastakia B Digiovanna JJ Bale SJ Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome Genet Med 2013 15 79 83 22918513
  4. [4]Solis DC Kwon GP Ransohoff KJ Li S Chahal HS Ally MS Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry JAMA Dermatol 2017 153 189 92 27902821
  5. [5]Shah M Mavers M Bree A Fosko S Lents NH Quality of life and depression assessment in nevoid basal cell carcinoma syndrome Int J Dermatol 2011 50 268 76 21342158
  6. [6]Tang JY Mackay-Wiggan JM Aszterbaum M Yauch RL Lindgren J Chang K Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome N Engl J Med 2012 366 2180 8 22670904 PMC4362529
  7. [7]MacCormack MA Photodynamic therapy Adv Dermatol 2006 22 219 58 17249304
  8. [8]Anand S Ortel BJ Pereira SP Hasan T Maytin EV Biomodulatory approaches to photodynamic therapy for solid tumors Cancer Lett 2012 326 8 16 22842096 PMC3459352
  9. [9]Karrer S Bosserhoff AK Weiderer P Landthaler M Szeimies RM Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts J Invest Dermatol 2003 120 325 31 12542540
  10. [10]Karrer S Bosserhoff AK Weiderer P Landthaler M Szeimies RM Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts Br J Dermatol 2004 151 776 83 15491416
  11. [11]Dijkstra AT Majoie IM van Dongen JW van Weelden H van Vloten WA Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen’s disease and basal cell carcinoma J Eur Acad Dermatol Venereol 2001 15 550 4 11843215
  12. [12]Karrer S Szeimies RM Hohenleutner U Heine A Landthaler M Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid Dermatology 1995 190 218 22 7599385
  13. [13]Kopera D Cerroni L Fink-Puches R Kerl H Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome J Am Acad Dermatol 1996 34 937 9 8621834
  14. [14]Lane JE Allen JH Lane TN Lesher JL Jr Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy J Cutan Med Surg 2005 9 336 40 16699902
  15. [16]Mougel F Debarbieux S Ronger-Savle S Dalle S Thomas L Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy Dermatology 2009 219 138 42 19590166
  16. [17]Girard C Debu A Bessis D Blatiere V Dereure O Guillot B Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children J Eur Acad Dermatol Venereol 2013 27 e171 5 22500823
  17. [18]Oseroff AR Shieh S Frawley NP Cheney R Blumenson LE Pivnick EK Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy Arch Dermatol 2005 141 60 7 15655143
  18. [19]Itkin A Gilchrest BA delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome Dermatol Surg 2004 30 1054 61 15209801
  19. [20]Gilchrest BA Brightman LA Thiele JJ Wasserman DI Photodynamic therapy for patients with Basal cell nevus syndrome Dermatol Surg 2009 35 1576 81 19681991
  20. [21]Haller JC Cairnduff F Slack G Schofield J Whitehurst C Tunstall R Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy Br J Dermatol 2000 143 1270 5 11122032
  21. [22]Warren CB Karai LJ Vidimos A Maytin EV Pain associated with aminolevulinic acid-photodynamic therapy of skin disease J Am Acad Dermatol 2009 61 1033 43 19925929 PMC3529571
  22. [23]Babes A Sauer SK Moparthi L Kichko TI Neacsu C Namer B Photosensitization in Porphyrias and Photodynamic Therapy Involves TRPA1 and TRPV1 J Neurosci 2016 36 5264 78 27170124 PMC6601806
  23. [24]Wiegell SR Skodt V Wulf HC Daylight-mediated photodynamic therapy of basal cell carcinomas - an explorative study J Eur Acad Dermatol Venereol 2014 28 169 75 23294223
  24. [27]Morton CA MacKie RM Whitehurst C Moore JV McColl JH Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response Arch Dermatol 1998 134 248 9 9487227
  25. [28]Thissen MR Schroeter CA Neumann HA Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique Br J Dermatol 2000 142 338 9 10730770
  26. [29]Christensen E Skogvoll E Viset T Warloe T Sundstrom S Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up J Eur Acad Dermatol Venereol 2009 23 58 66 18803580
  27. [30]Mosterd K Thissen MR Nelemans P Kelleners-Smeets NW Janssen RL Broekhof KG Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial Br J Dermatol 2008 159 864 70 18717680
  28. [31]Kabingu E Oseroff AR Wilding GE Gollnick SO Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy Clin Cancer Res 2009 15 4460 6 19549769 PMC2805024

Cited by

Sorted by citations

Authors
Maytin, E. V., Kaw, U., Ilyas, M., Mack, J. A., & Hu, B.
Affiliations
  • Harvard University (US)
  • Cleveland Clinic Research (US)
  • Cleveland Clinic (US)
Corresponding author
Maytin, Edward V.
ORCID
Venue
Photodiagnosis and Photodynamic Therapy
Publisher
Elsevier BV
Published
2018-06
Volume
22
Pages
7-13
ISSN
1572-1000 (ISSN-L)
DOI
10.1016/j.pdpdt.2018.02.009
PMC
PMC5985214
OpenAlex
W2792854179
Cited by
55
References
3
Citations by year
2026: 1 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 15 · 2019: 5 · 2018: 1
FWCI
5.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Photodiagnosis and Photodynamic Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • DUSA/Sun Pharmaceuticals [Investigator-Initiated Study
  • National Institutes of Health (P01-CA84203)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
Keywords
photodynamic therapy, basal cell carcinoma, Gorlin syndrome, blue light, red light, 5-aminolevulinic acid, tumor clearance, treatment efficacy and safety
MeSH terms
Adult, Aminolevulinic Acid, Basal Cell Nevus Syndrome, Basal Cell Carcinoma, Carcinoma, Basal Cell, Female, Humans, Light, Male, Middle Aged, Photochemotherapy, Pilot Projects, Skin Neoplasms, Patient Satisfaction, Photosensitizing Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review